Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Zinger Key Points
  • The company noted that none of the other three higher-dosing groups (30, 40, and 60 mg) reached statistical significance.
  • The analyst says the 20 mg dose positions '568 as a strong contender among selective muscarinic agonist.

Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.

The new data showed that the once-daily 20 mg dose of NBI-‘568 induced an average 18.2-point reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) after six weeks, compared to 10.8 points in the placebo group.

That 7.5-point difference reached statistical significance with a p-value of p=0.011.

The company noted that none of the other three higher-dosing groups (30, 40, and 60 mg) reached statistical significance.

Piper Sandler upgraded the stock from Neutral to Overweight, with a price target of $159, up from $131, noting that data around 20 mg puts ‘568 squarely “in the game.”

“Though the hand-wringing over Phase 2 data for NBI-1117568 in adults with schizophrenia, is not lost on us.”

The 20 mg dose positions ‘568 as a strong contender among selective muscarinic agonists, offering a promising alternative in the antipsychotic field that moves away from the safety concerns associated with atypical antipsychotics, the analyst notes.

In a field where individualized treatment responses and frequent cycling between options are common, adding another selective muscarinic agonist, even one with a similar profile, holds value. Though the analyst notes that there’s still much to learn about ‘568, but its inclusion in the treatment arsenal is beneficial.

Price Action: NBIX stock is up 3.64% at $128.26 at the last check on Thursday.

Read Next:

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsUpgradesHealth CareTop StoriesAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert IdeasStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!